Drug intelligence / Profile preview

opevesostat + olaparib

Development stage: Unknown
Lead developer: Merck
Modality: Small Molecules
Administration: Oral

Overview

**Opevesostat + olaparib** is an investigational oral drug combination under clinical development for the treatment of metastatic castration-resistant prostate cancer (mCRPC)[3][5][7]. Opevesostat (MK-5684) is a small molecule with unknown detailed mechanism, being studied primarily as a targeted therapy for prostate cancer[3][7]. Olaparib is a small molecule poly(ADP-ribose) polymerase (PARP) inhibitor, approved for several cancers, and works by inhibiting PARP enzymes, impairing DNA repair in BRCA-mutated and homologous recombination-deficient cancers, enhancing cancer cell death[4][6][8]. The combination is intended to block parallel or complementary DNA repair/alive pathways in prostate cancer, potentially improving patient outcomes over single agent therapy.

Other names: opevesostat tosilate + olaparib

Targets

TNKS (Poly(ADP-ribose) Polymerase 5a)CYP11A1 (Cholesterol side chain cleavage enzyme)PARP2 (Poly (adp-ribose) polymerase 2)TNKS2 (Tankyrase 2)

Beyond the preview

Go deeper on opevesostat + olaparib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on opevesostat + olaparib.

Explore the full profile